arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Moderna, Inc.

MRNA
$234.38 ▼ -23.32 (-9.05%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
37 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
25
Health
Poor
Bearish
auto_awesome

Analytical Summary

Moderna, Inc. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $93.3B
Dividend Yield —
Revenue Growth 2.1% ↘
Op. Margin None
ROIC -11.3% ↗
FCF / Share $-1.41 ↗
Trailing P/E —
Price / Book 13.8x
FCF Yield —
Debt / Equity 0.09
info Valuation on last close. End-of-day price, Nov 5, 2026.

37-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$145.00M
↑ +2.1% —
Net Income Profit after all expenses
$-782.00M
↑ +5.2% —
Operating Margin Operating profit as % of sales
-356.8%
↓ -182.3% 1th
FCF / Share Free cash flow per share
$-1.41
↑ +19.3% —
Long-Term Debt Long-term obligations
$591.00M
— +0.2% —
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
2
Returns
22
Financial Health
47
Cash Quality ↓
50

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 11 years · 37 quarters